LSD for Health & Longevity
Evidence Review created on 10/26/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Lysergic Acid Diethylamide, Lysergide, LSD-25, Delysid, MM120, DT120, Acid
Motivation
Lysergic acid diethylamide (LSD) is a laboratory-made compound derived from a grain fungus. Tiny amounts change perception, mood and thinking for most of a day by acting on one type of serotonin receptor in the brain. It is of interest because a single supervised session is being tested as a treatment for persistent anxiety and depression, and because some people take very small, non-intoxicating amounts in the hope of better mood and brain health.
LSD was studied widely in the 1950s and 1960s as an aid to psychotherapy, before legal restrictions halted most research for decades. Controlled trials resumed in Switzerland in the 2010s, and a company is now running late-stage trials of a single-dose tablet. Separately, laboratory work on the brain’s ability to form new connections has drawn the attention of people focused on healthy aging.
This review examines what human and laboratory evidence shows about the benefits and risks of LSD for health-focused adults, covering full-dose sessions and repeated low doses, the safety measures used in research, drug interactions, and the open questions that current trials are designed to answer.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists overviews and expert discussions that cover LSD, or the psychedelic-therapy category it belongs to, in depth.
-
Dr. Matthew Johnson: Psychedelic Medicine - Andrew Huberman
A Johns Hopkins psychedelic researcher explains how LSD and related compounds are tested in clinical trials, how sessions are run, and which people face heightened risks, including flashbacks.
-
Psychedelic Drugs for Alzheimer’s Treatment - Josh Conway
Summarizes the case that psychedelics acting on the serotonin 2A receptor (a brain receptor shaping perception), including LSD, could support neuroplasticity (new neural connections) in Alzheimer’s disease, with caveats about hallucinogenic effects.
-
RHR: The Emerging Field of Psychedelic-Assisted Psychotherapy, with Dr. Ingmar Gorman - Chris Kresser
Covers psychedelic-assisted psychotherapy, the treatment approach in which LSD is tested, including first-generation psychedelics that, like LSD, act on the serotonin 2A receptor, unsupervised use and adulterated illicit supply.
-
Roland Griffiths, Ph.D. on Psilocybin, Psychedelic Therapies & Mystical Experiences - Rhonda Patrick
Johns Hopkins researcher Roland Griffiths covers psilocybin-assisted therapy for cancer-related anxiety and depression, mystical experiences and risks; psilocybin, like LSD, is a classic psychedelic acting on the serotonin 2A receptor.
-
Covers psychedelic-assisted psychotherapy with serotonin-acting drugs, including LSD’s research history, its 1970s scheduling, and a case combining MDMA (ecstasy, which releases serotonin) with LSD (which activates the serotonin 2A receptor).
Life Extension mentions LSD only in passing inside broader topic pages (Life Extension Depression protocol; Life Extension Anxiety protocol), so no item from it met the depth requirement.
Grokipedia
-
Broad encyclopedic overview of LSD’s chemistry, discovery, receptor pharmacology, duration of effects, toxicity, legal history and renewed clinical research.
Examine
-
Examine’s intervention page summarizing preliminary evidence for psychiatric uses such as depression and anxiety, with a research feed of individual trial summaries.
ConsumerLab
No ConsumerLab article on LSD exists. ConsumerLab tests dietary supplements, and LSD is a controlled substance rather than a supplement.
Systematic Reviews
The following systematic reviews and meta-analyses (statistical pooling of results across studies) cover LSD’s psychiatric effects, low-dose use, and adverse events.
-
Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials - Fernandes-Nascimento et al., 2025
Pools 11 randomized (chance-assigned) trials with 682 patients; small benefit for substance use disorders; most trials date from the 1960s–1970s.
-
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials - Krebs & Johansen, 2012
Six historical randomized trials (536 participants) show a single LSD dose within alcoholism programs reduced alcohol misuse at first follow-up.
-
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases - Schipper et al., 2024
Cochrane review: psilocybin or LSD therapy may reduce anxiety and depression in serious illness; certainty is low because participants could tell their treatment.
-
Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis - Meshkat et al., 2026
Twenty-four studies in healthy adults: randomized LSD and psilocybin microdosing trials show no consistent benefit over placebo for mood, anxiety or stress.
-
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis - Hinkle et al., 2024
Covers 3,504 participants: serious adverse events occurred only in patients with pre-existing disorders; common events were headache, anxiety, nausea and fatigue.
Mechanism of Action
LSD is a semisynthetic ergoline (an ergot-derived compound) that acts mainly as a partial agonist (activating a receptor less than fully) at the serotonin 2A receptor (5-HT2A, a brain serotonin receptor shaping perception and mood). Ketanserin, a 5-HT2A antagonist (a drug that blocks the receptor), prevents or reverses the psychedelic response in Basel-group studies (Holze 2021; Becker 2023); the group’s hospital licensed its data to Definium (formerly MindMed), the LSD-tablet developer, for royalties (MindMed licensing press release). Selectivity is low: LSD also binds 5-HT1A, 5-HT2C, heart-valve 5-HT2B and dopamine receptors; a protein “lid” over the binding pocket slows its release (Wacker 2017).
Competing explanations:
- Experience-driven: mystical-type experiences during the session correlated with later anxiety reduction (Holze 2023).
- Plasticity-driven: in mice, LSD binds TrkB (the receptor for brain-derived neurotrophic factor, BDNF, a growth signal for neurons) and promotes neuroplasticity independently of 5-HT2A (Moliner 2023); cell studies also implicate mTOR (mechanistic target of rapamycin, a nutrient-sensing growth pathway) (Ly 2018).
- Expectancy-driven: a review argues that failed blinding (participants correctly guessing their treatment) may inflate trial effects (Szigeti 2024).
Oral LSD peaks in plasma after about 1.5 hours, distributes moderately into tissues (volume of distribution about 37–46 liters), has a plasma half-life (time for blood levels to halve) of about 2.6 hours, reaches its effect site with a 21–48-minute lag, and acts for 8–12 hours at 100–200 micrograms (µg) (Dolder 2017). The liver converts it mainly to inactive 2-oxo-3-hydroxy-LSD, with CYP2D6 (a liver enzyme that breaks down many drugs) contributing substantially (Vizeli 2021).
Historical Context & Evolution
Albert Hofmann synthesized LSD at Sandoz in 1938 as a candidate circulatory and respiratory stimulant, and discovered its psychoactive effects in 1943 (Hofmann 1979). From 1949 to 1966 Sandoz supplied it to psychiatrists as Delysid (Liechti 2017), and was studied as a “model psychosis” (psychosis: loss of contact with reality), an aid to psychotherapy, and a treatment for alcoholism; a meta-analysis of alcoholism trials found less drinking at early follow-up (Krebs 2012). Many studies fell short of efficacy standards introduced in 1962, so an FDA (United States Food and Drug Administration) scientist treats them as pilot data, neither proving nor disproving benefit (Bonson 2018).
Political pressure after recreational spread halted research in the early 1970s (Liechti 2017), and LSD is listed in United States Schedule I (the most restrictive category, for drugs deemed to lack accepted medical use) (21 CFR 1308.11). Late-1960s reports of chromosome damage were re-examined in a review of 21 human studies, which found no detectable damage from pure LSD at moderate doses (Dishotsky 1971).
Controlled research resumed with a Swiss pilot trial in 2014 (Gasser 2014). Interest for health optimization grew along two lines: self-experimentation with microdoses, popularized by James Fadiman (Fadiman 2019), and laboratory evidence of anti-inflammatory effects, which prompted Eleusis-sponsored low-dose trials in older adults aimed at Alzheimer’s disease (Family 2020). In 2026, company-run late-stage trials reported single-dose anxiety and depression results (Definium Voyage press release; Definium Emerge press release), while a meta-analysis found microdosing largely failed to confirm self-reported benefits (Meshkat 2026).
Expected Benefits
High 🟩 🟩 🟩
Reduced anxiety symptoms ⚠️ Conflicted
One or two sessions lower anxiety for 12–16 weeks in generalized anxiety disorder (persistent, excessive worry) and serious illness. Two research groups contributed: Swiss academics (Gasser 2014, advocacy-funded; Holze 2023, a crossover trial giving each patient both treatments), whose Basel hospital holds a royalty licence with Definium, and Definium itself, the LSD-tablet developer funding the largest dose-finding trial (Robison 2025) and two press-released Phase 3 (late-stage) trials. A 2025 review of randomized trials found no conclusive anxiety benefit (Fernandes-Nascimento 2025). Net reading: replicated benefit; the largest trials postdate that review.
Magnitude: On the HAM-A (Hamilton Anxiety Rating Scale, a clinician-rated 0–56 anxiety score), 100 µg produced a 5.0-point greater reduction than placebo at week 4 (95% CI, the range likely to contain the true effect, −9.6 to −0.4) (Robison 2025) and a 5.4-point greater reduction at week 12 in Voyage (Definium Voyage press release) and 5.1 points in Panorama (Definium Panorama press release), CIs not reported.
Reduced alcohol misuse ⚠️ Conflicted
A single high dose within alcoholism programs reduced misuse in a meta-analysis of six randomized controlled trials (studies assigning treatment by chance against a comparison) from the 1960s run by separate North American groups, including Ludwig, Hollister and Smart (Krebs 2012). Some individual trials found no lasting advantage over standard treatment (Ludwig 1969), and a systematic review notes that LSD and control groups converged at long-term follow-up in some studies (Fuentes 2019). The net reading is a short-term reduction in drinking that is consistent across trials but of uncertain durability.
Magnitude: Odds ratio (the odds of improvement with LSD divided by the odds with control) 1.96 (95% CI 1.36 to 2.84) at first reported follow-up; 59% of LSD patients versus 38% of control patients improved (Krebs 2012).
Medium 🟩 🟩
Reduced depressive symptoms ⚠️ Conflicted
LSD sessions reduce depressive symptoms in major depressive disorder (persistent low mood with loss of interest) and in anxious patients. Evidence comes from the Basel group (Holze 2023; Müller 2025) and Definium’s Phase 3 Emerge trial, reported only by press release. In Müller 2025 clinician-rated gains became uncertain after baseline adjustment, and self-ratings showed an uncertain difference (−7.9; 95% CI −16.0 to 0.3, a range including no effect). The net reading is a consistent direction of benefit across two groups, with the largest trial industry-funded and not yet peer-reviewed.
Magnitude: On the MADRS (Montgomery–Åsberg Depression Rating Scale, 0–60), one 100 µg dose produced an 8.1-point greater reduction than placebo at week 6, CI not reported (Definium Emerge press release); co-occurring depression fell 7.0 points more than placebo on the 21-item Hamilton Depression Rating Scale at 16 weeks (95% CI −10.8 to −3.2) (Holze 2023).
Higher pain tolerance
A 20 µg dose, below the threshold for marked perceptual effects, increased tolerance of painful cold water and lowered pain and unpleasantness ratings in 24 healthy volunteers in a single placebo-controlled trial from Maastricht with Basel co-authors and a Beckley Foundation (psychedelic-research charity) co-author (Ramaekers 2021). Laboratory-induced pain in healthy people may not predict effects on chronic pain, which has not been tested.
Magnitude: 20 µg increased cold-water pain tolerance and reduced painfulness and unpleasantness relative to placebo; the paper presents the size of the difference only graphically and reports no numeric outcome figure (Ramaekers 2021).
Low 🟩
Better mood and cognition from microdosing ⚠️ Conflicted
Repeated 10 µg doses lifted mood on dosing days (Murphy 2023, MindBio-sponsored), but 13–26 µg doses improved neither mood nor cognition in healthy adults (de Wit 2022), and microdosing failed against placebo for ADHD (attention-deficit/hyperactivity disorder) (Mueller 2025, MindMed-sponsored) or depression (MindBio LSDDEP2 press release). Net reading: no sustained benefit.
Magnitude: Depressive symptoms in healthy adults: standardized mean difference (effect in standard-deviation units) −0.19 versus placebo (95% CI −0.56 to 0.19) (Meshkat 2026).
Lasting well-being after a full-dose session
Healthy volunteers reported higher well-being and life satisfaction 1 and 12 months after one 200 µg dose in an uncontrolled Basel follow-up (Schmid 2018). A meta-analysis found lasting mood and social gains, but pooled LSD with psilocybin and ayahuasca, mostly in patients (Goldberg 2020).
Magnitude: Between-group effect sizes (Hedges’ g, the difference in standard-deviation units) across classic psychedelics of 0.87 (95% CI 0.46 to 1.28) for negative mood, 0.89 (95% CI 0.52 to 1.25) for positive mood, 1.13 (95% CI 0.76 to 1.51) for social and 0.84 (95% CI 0.53 to 1.16) for existential outcomes (Goldberg 2020; figures follow the full-text table, as the abstract’s stated range of 0.84 to 1.08 omits the social value of 1.13); the LSD-only follow-up reports significant rises without an outcome figure (no control group) (Schmid 2018).
Lower odds of heart disease and diabetes
People reporting lifetime classic-psychedelic use had lower odds of past-year heart disease and diabetes in a United States national survey (Simonsson 2021). The evidence is indirect: it concerns psychedelics as a class, LSD use alone showed no independent association, doses were unknown, and lifestyle differences may explain the link.
Magnitude: Adjusted (for other measured factors) odds ratio 0.77 for heart disease (95% CI 0.65 to 0.92) and 0.88 for diabetes (95% CI 0.78 to 0.99) versus non-users; past-year prevalence 2.29% versus 4.49% for heart disease and 3.95% versus 7.69% for diabetes (unadjusted) (Simonsson 2021).
Fewer cluster headache attacks
In an interview series of 53 people with cluster headache (bouts of severe one-sided head pain) who self-treated with psilocybin or LSD, 7 of the 8 LSD users reported ended bouts and 4 of 5 reported longer remissions (Sewell 2006). The data are uncontrolled and self-selected.
Magnitude: 7 of 8 LSD users reported termination of a cluster period and 4 of 5 reported remission extension (no control group) (Sewell 2006).
Speculative 🟨
Brain plasticity and healthier brain aging
LSD increases neuron branching and synapse formation in cell and rodent studies via 5-HT2A and TrkB signaling (Ly 2018; Moliner 2023). Human data show only transient plasma BDNF rises; the basis is mechanistic.
Longer lifespan
Very low LSD concentrations extended worm lifespan by up to 17.6% through serotonin receptors (Carrilho 2026), and psilocybin, a related compound, improved survival in aged mice (Kato 2025). The basis is animal data only.
Benefit-Modifying Factors
- CYP2D6 genotype: People with no functional CYP2D6 (poor metabolizers) have about 75% higher LSD exposure and longer, stronger effects (Vizeli 2021); whether this changes therapeutic benefit is untested.
- Baseline symptom scores: Efficacy trials enrolled moderate-to-severe anxiety (HAM-A 20 or higher) (Robison 2025) or depression (Müller 2025); a meta-analysis found no consistent benefit from microdosing in healthy adults without symptoms (Meshkat 2026).
- Baseline biomarkers: No blood biomarker is known to predict therapeutic benefit; even plasma LSD concentrations did not predict the strength of acute effects across individuals (Dolder 2017).
- Quality of the session experience: Mystical-type experiences predicted larger anxiety reductions (Holze 2023); pre-dose well-being, anxiety and trait openness shaped the experience (Vizeli 2024).
- Sex: In a pooled analysis of 213 healthy volunteers, sex and body weight did not significantly predict acute drug effects (Vizeli 2024); efficacy trials were too small to detect sex differences.
- Age: Efficacy trials enrolled adults up to 74; a systematic review found fewer than 1.4% of psychedelic-trial participants were 65 or older (Bouchet 2024), so benefit at older ages is largely unmeasured.
- Concurrent antidepressants: Long-term SSRI (selective serotonin reuptake inhibitor, the most common antidepressant class) use blunted LSD’s effects in user reports (Bonson 1996), although paroxetine did not reduce pleasant effects in a controlled trial (Becker 2025).
- Pre-existing conditions: Benefit has been shown in generalized anxiety disorder, major depression, illness-related anxiety and historical alcoholism; it was absent in ADHD (Mueller 2025).
Potential Risks & Side Effects
High 🟥 🟥 🟥
Acute perceptual changes and psychological distress
Visual perceptual changes are expected, while anxiety, fear or a distressing (“challenging”) experience occurs in a dose-dependent minority. Evidence comes from Definium’s dose-finding trial (Robison 2025), pooled Basel placebo-controlled studies (Holze 2022), and an Auckland home-microdosing trial in which four participants withdrew for anxiety (Murphy 2023). Effects resolve as the drug wears off, usually within 6–12 hours, but unsupervised distress can lead to dangerous behavior (Johnson 2008).
Magnitude: At 100 µg, visual perceptual changes in 92.5% versus 10.3% with placebo (Robison 2025); “bad drug effect” ratings above half the scale in 27% of administrations versus 0% with placebo (Holze 2022).
Nausea, headache and next-day fatigue
Nausea and headache are the most common physical adverse events, and tiredness or headache can persist into the next day. These were replicated by Definium (Robison 2025) and the Basel group (Holze 2022), and a meta-analysis found similar rates for LSD and psilocybin (Hinkle 2024). Symptoms are mild to moderate and transient.
Magnitude: At 100 µg, nausea 40.0% versus 7.7% and headache 35.0% versus 23.1% with placebo (Robison 2025); next-day tiredness 54% versus 25% with placebo (Holze 2022).
Medium 🟥 🟥
Rises in blood pressure, heart rate and body temperature
LSD is sympathomimetic (it stimulates the “fight-or-flight” nervous system), moderately raising blood pressure, heart rate and temperature for several hours. Data come mainly from pooled Basel studies (Holze 2022), with blood-pressure rises also at 20 µg in a Maastricht study co-authored by Basel researchers (Ramaekers 2021). No systolic (upper-number) blood pressure exceeded 180 mmHg in 131 healthy-volunteer administrations; relevance grows with cardiovascular disease.
Magnitude: At 100 µg, mean peak systolic blood pressure 12 mmHg higher than with placebo (141 versus 129 mmHg) and peak heart rate 13 beats/min higher (86 versus 73 beats/min); heart rate above 100 beats/min in 20% versus 0% (Holze 2022).
Low 🟥
Serious psychiatric reactions ⚠️ Conflicted
Serious adverse events, such as suicidal behavior and psychosis, affected about 4% of participants with pre-existing psychiatric disorders and no healthy volunteers in a review pooling classic psychedelics (Hinkle 2024). Pooled trials showed no excess severe events versus placebo (Hsu 2024). Net reading: rare, concentrated in vulnerable patients.
Magnitude: Serious adverse events in about 4% of participants with pre-existing neuropsychiatric disorders and none of the healthy participants across LSD, psilocybin and DMT (dimethyltryptamine, a short-acting psychedelic) studies (no control group) (Hinkle 2024).
Hypomania and mania
A systematic review links psychedelics to hypomania (milder mania) and mania (abnormally elevated, energized mood), usually brief, and most common with bipolar I disorder (full manic episodes), family vulnerability or unsupervised use (Eskinazi 2026). Evidence is indirect: LSD was pooled with other psychedelics and MDMA.
Magnitude: Mood-switch symptoms, hypomania or mania in 5.8% of participants in controlled psilocybin trials for depression, up to 30% in naturalistic studies of people with bipolar disorder (no control group); the review reports no LSD-specific or placebo-group rate (Eskinazi 2026).
Flashbacks and persisting perceptual changes
Brief recurrences of drug-like visual effects followed LSD in 7.8% of healthy Basel volunteers, mostly mild and within a week; none met criteria for hallucinogen persisting perception disorder (lasting, distressing perceptual changes) (Müller 2022). A review places persistent cases mainly after illicit use (Halpern 2003).
Magnitude: Flashbacks in 7.8% of healthy participants after LSD (no control group); the study reports no placebo-condition rate (Müller 2022).
Injury from impaired judgment outside supervised settings
A systematic review found that catastrophic events reported in recreational settings have not occurred in contemporary trials (Hinkle 2024); distress can provoke dangerous behavior such as leaving a safe location (Johnson 2008). Evidence is case-based.
Magnitude: Not quantified in available studies. Only case reports from non-clinical settings describe such injuries, without a denominator or comparison group.
Severe poisoning from very high or mistaken doses
In one cluster, four people who inhaled LSD powder sold as cocaine developed agitation, vomiting, high blood pressure and sedation; all needed hospital care, one a breathing tube in intensive care, and none had lasting injury (Roberts 2021). Evidence is limited to case reports; measured pharmaceutical doses avoid this risk.
Magnitude: Not quantified in available studies. Only case reports and small case series describe such poisonings, without a denominator or comparison group.
Speculative 🟨
Heart valve damage with frequent repeated dosing
A systematic review found high LSD affinity for 5-HT2B receptors, which drive drug-induced valve disease, but no human cases (Xu 2026); a MindBio-sponsored 8-week microdosing trial showed none (Daldegan-Bueno 2026). Basis: mechanistic, animal data.
Risk-Modifying Factors
- CYP2D6 genotype: Poor metabolizers have about 75% higher exposure and longer effects (Vizeli 2021); lower CYP2D6 function also correlated with more acute anxiety (Vizeli 2024).
- Baseline blood pressure and mood: LSD adds roughly 12 mmHg to peak systolic pressure at 100 µg (Holze 2022), which matters more with high baseline values; pre-dose anxiety predicted a more anxious experience (Vizeli 2024).
- Sex: Sex did not significantly predict autonomic or subjective responses (Vizeli 2024); pregnancy is a separate concern because no human safety data exist for pure LSD.
- Pre-existing psychiatric disorders: In a systematic review, serious psychiatric events occurred only in patients with pre-existing disorders (Hinkle 2024); personal or family history of psychosis is the main screening exclusion in safety guidelines (Johnson 2008).
- Cardiovascular and valve disease: Blood pressure and heart rate rises (Holze 2022) and 5-HT2B activation described in a systematic review (Xu 2026) carry more weight with coronary disease, uncontrolled hypertension or existing valve abnormalities.
- Age: Low doses (5–20 µg) caused no balance or cognitive impairment in adults aged 55–75 (Family 2020); a systematic review found full-dose safety data beyond 65 sparse (Bouchet 2024).
- Dose and setting: Anxiety and ego dissolution (loss of the sense of self) rise further above 100 µg (Holze 2021); 80% of volunteers said the controlled setting made them feel safe (Holze 2022).
Key Interactions & Contraindications
Documented interactions:
- SSRIs (selective serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine): Long-term use blunted LSD effects in 28 of 32 users (Bonson 1996). Consequence: weaker session effects. Mitigation: no dose change with CYP2D6-inhibiting SSRIs; a higher dose may suit others (Becker 2025).
- Paroxetine, a CYP2D6 inhibitor (an agent that slows this enzyme): Raised LSD peak levels 1.4-fold and total exposure 1.5-fold, while reducing anxiety and nausea (Becker 2025). Investigators judged no LSD dose change necessary.
- Paroxetine and heart effects: No interaction found on blood pressure, heart rate or QTc (a heart-rhythm interval on the electrocardiogram) (Becker 2025).
- Tricyclic antidepressants (older antidepressants such as imipramine, desipramine, clomipramine): Users reported stronger physical, hallucinatory and psychological responses (Bonson 1996). Consequence: risk of an overwhelming session; lower LSD doses are the usual mitigation.
- Lithium — Avoid: Seizures occurred in 47% of 62 online reports of lithium combined with classic psychedelics, and 39% involved medical attention (Nayak 2021); users also reported stronger LSD responses (Bonson 1996).
- Lamotrigine (an anti-seizure drug and mood stabilizer): No interaction found: none of 34 online reports of lamotrigine combined with classic psychedelics involved seizures, and most described an unchanged experience (Nayak 2021).
- MAO inhibitors (monoamine oxidase inhibitors, antidepressants such as phenelzine, tranylcypromine): Users reported weaker LSD responses (Bonson 1996). Consequence: blunted session effects.
- Ketanserin (serotonin 2A blocker): Given 1 hour after LSD, it shortened effects from 8.5 to 3.5 hours and reduced cardiovascular effects, with no pharmacokinetic interaction (change in LSD blood levels) found (Becker 2023). Used as a planned or rescue option.
- MDMA (3,4-methylenedioxymethamphetamine, “ecstasy”, an empathogen, a drug that heightens feelings of closeness): Raised LSD blood levels, prolonged effects, and increased blood pressure and heart rate more than LSD alone (Straumann 2023). Consequence: longer, more stimulating sessions.
- Antipsychotics (drugs for psychosis such as chlorpromazine, risperidone, olanzapine, haloperidol): Chlorpromazine blunted LSD effects in some early human studies (Isbell 1957) but intensified them in others (Abramson 1960), a systematic review reports (Halman 2024). Consequence: unpredictable session effects; ketanserin is the studied rescue option.
- Cannabis: In a prospective survey of 321 classic-psychedelic users (LSD not analyzed separately), concurrent cannabis was associated with more intense experiences, rising with cannabis dose, and a non-linear rise in challenging experiences (Kuc 2022). Consequence: more intense, sometimes anxious sessions; usually avoided on session days.
- Alcohol: In retrospective interviews of 22 LSD and/or psilocybin users, LSD completely blocked subjective alcohol effects in 86.7% of those who combined them, and diminished them in the rest (Barrett 2000). Consequence: blunted perception of alcohol intoxication.
- 5-HTP (5-hydroxytryptophan, a serotonin precursor) and L-Tryptophan (supplements): Human pretreatment studies reported that 5-HTP alleviated LSD’s psychological effects (Brengelmann 1958; Pare 1963); tryptophan pretreatment was also tested (Vojtěchovský 1967). Consequence: possibly weaker session effects; usually paused before sessions.
- Niacin (vitamin B3, high-dose supplement): Pretreatment delayed and prevented most LSD perceptual changes, and dosing after LSD attenuated its effects, in an early human study (Agnew 1955), a systematic review reports (Halman 2024). Consequence: weaker session effects; usually paused before sessions.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Other serotonergic drugs (tramadol, dextromethorphan, linezolid, triptans, the migraine drugs such as sumatriptan): Inferred from additive serotonergic activity. Consequence: theoretical serotonin syndrome (agitation, fever, tremor from excess serotonin), not reported in LSD trials; usually kept to separate days.
- Stimulants and decongestants (amphetamine, methylphenidate, pseudoephedrine, high-dose caffeine): Inferred from additive sympathomimetic effects. Consequence: higher blood pressure and heart rate; usually avoided on session days.
- Inhibitors of other LSD-metabolizing enzymes (fluvoxamine for CYP1A2, a caffeine-metabolizing enzyme; fluconazole for CYP2C9, a drug-metabolizing enzyme): Inferred from test-tube metabolism data (Luethi 2019). Consequence: possibly higher exposure; genetic variants of these enzymes had no effect (Vizeli 2021), so the impact is likely small.
- Bupropion and other seizure-threshold-lowering drugs: Inferred from seizures with lithium plus psychedelics. Consequence: possible seizure risk; the combination is usually avoided.
- St John’s wort (supplement): Inferred from additive serotonergic activity and enzyme induction (speeding up drug metabolism). Consequence: theoretical serotonin toxicity or altered LSD levels; usually paused before sessions.
- Yohimbine and high-dose caffeine supplements: Inferred from additive blood-pressure and anxiety effects. Consequence: more cardiovascular strain and anxiety; usually avoided on session days.
- Sauna or strenuous heat exposure on session days: Inferred from LSD’s rise in body temperature (Holze 2022). Consequence: additive heat stress; usually avoided until effects resolve.
Populations who should avoid LSD:
- Personal or first-degree family history of psychotic disorders (schizophrenia, schizoaffective disorder, psychosis combined with major mood episodes) or bipolar I disorder (bipolar disorder with full manic episodes): Excluded under published human hallucinogen safety guidelines because of prolonged psychosis risk (Johnson 2008).
- People taking lithium: Seizure reports in 47% of combined-use accounts (Nayak 2021).
- Uncontrolled hypertension (130/80 mmHg or higher despite treatment), recent heart attack or stroke, or arrhythmia (irregular heart rhythm): Inferred from LSD’s cardiovascular rises (Holze 2022); threshold from the 2017 American College of Cardiology/American Heart Association guideline, written by societies whose members treat hypertension (Whelton 2018).
- Existing heart valve disease: Inferred from 5-HT2B activation described in a systematic review; no human data (Xu 2026).
- Pregnancy and breastfeeding: Inferred from the absence of human safety data; a review that found no evidence of a teratogenic (birth-defect-causing) effect of pure LSD still held that any drug use in pregnancy requires benefits that clearly outweigh its hazards (Dishotsky 1971).
- Epilepsy or other seizure disorders: Inferred from seizure reports with lithium plus psychedelics and convulsive serious adverse events in a systematic review (Hinkle 2024); no controlled data.
- Current suicidal intent or unstable severe psychiatric illness: A systematic review found serious events concentrated in patients with pre-existing disorders (Hinkle 2024).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Psychiatric screening before any session: Safety guidelines exclude people with a personal or family history of psychosis or bipolar I (Johnson 2008), to reduce the risk of prolonged psychotic reactions.
- Supervised setting with trained monitors: Two monitors, preparation sessions and a safe room (Johnson 2008) reduce acute distress and dangerous behavior during the 8–12-hour effect window.
- Moderate dose selection: 100 µg reached the ceiling for positive effects, while anxiety kept rising toward 200 µg (Holze 2021), limiting distressing experiences.
- Blood pressure stop threshold: Blood pressure is measured before dosing and hourly; dosing is deferred above 140/90 mmHg, the hypertension cutoff of Basel LSD trials (NCT04865653), preventing compounded hypertension from LSD’s sympathomimetic rise.
- Rescue medication available: Ketanserin 40 mg reverses the LSD response (Becker 2023); benzodiazepines (sedatives such as lorazepam) are common practice for acute anxiety.
- Medication review: Lithium is stopped or avoided (Nayak 2021), and tricyclic antidepressants, MAO inhibitors and stimulants are reviewed, to prevent seizures, overwhelming sessions or excess cardiovascular strain.
- Verified substance only: Pharmaceutical-grade LSD in a supervised medical setting avoids illicit blotters, which frequently contain other drugs such as NBOMes (potent synthetic hallucinogens) (de Souza Boff 2020) that a review links to seizures and deaths (Zawilska 2020).
- Echocardiogram for repeated dosing: For regular microdosing beyond several weeks, a baseline and periodic echocardiogram (heart ultrasound) screens for the theoretical valve risk described in a systematic review (Xu 2026).
- No driving for 24 hours: Impaired balance and concentration affect 36–64% at 100 µg (Holze 2022); avoiding driving and machinery prevents injury.
- Integration follow-up: Post-session follow-up to detect worsening mood, suicidality or persisting perceptual changes (Johnson 2008) allows early treatment.
Therapeutic Protocol
Timing, cycling and titration steps below follow common practice unless cited.
- Single-dose regimen (industry): One 100 µg dose of lysergide as an orally disintegrating tablet, monitored for at least 8 hours (Definium Panorama press release; Robison 2025).
- Two-session assisted therapy (academic): Two 200 µg sessions with preparatory and integration psychotherapy (Holze 2023; Gasser 2014), or 100 µg then 200 µg for depression (Müller 2025).
- Microdosing regimen: About 10 µg every third day, popularized by James Fadiman (Fadiman 2019); trials used 5–20 µg every 4 days (Family 2020) or 20 µg twice weekly (Mueller 2025).
- Approach originators: Assisted therapy was revived by Peter Gasser and the Basel group of Matthias Liechti; the single-dose model by Definium; microdosing by James Fadiman.
- Time of day: Full doses are taken in the morning because effects last 8–11 hours at 100–200 µg (Holze 2022); microdoses are taken early to protect sleep.
- Half-life: Plasma half-life is about 2.6–2.7 hours (Dolder 2017; Holze 2021), and effects follow plasma levels with a lag of up to about an hour.
- Single versus split dose: Each session uses a single oral dose; splitting is not used in trials because it prolongs the effect window.
- Genetic factors: CYP2D6 poor metabolizers have about 75% higher exposure (Vizeli 2021); genotyping, or a lower first dose without it, is a common-practice adjustment.
- Sex differences: Trials do not adjust dose by sex; in healthy volunteers, sex and body weight did not predict acute drug effects (Vizeli 2024), and sex effects on therapeutic response are untested.
- Older adults: Low doses of 5–20 µg were tolerated at ages 55–75 (Family 2020); a systematic review found full doses in people over 65 rest on very few participants (Bouchet 2024).
- Baseline biomarkers: Baseline blood pressure, heart rhythm and symptom scores guide eligibility and track response; trials required a HAM-A of 20 or higher (Robison 2025).
- Pre-existing conditions: Benefit has been tested in generalized anxiety disorder and major depression (Robison 2025; Müller 2025); with CYP2D6-inhibiting SSRIs such as paroxetine, no LSD dose change is needed (Becker 2025); bipolar disorder treated with lithium excludes use (Nayak 2021).
Discontinuation & Cycling
- Episodic, not lifelong: Full-dose LSD is given as one or two sessions; in the Voyage extension, participants could receive up to four further doses over 40 weeks based on symptoms (Definium Voyage press release).
- Withdrawal effects: None described; LSD is not considered a drug of dependence (Johnson 2008).
- Tapering: Not required, as no withdrawal syndrome exists; stopping a microdosing course abruptly is standard.
- Tolerance and cycling: Daily dosing produces rapid tolerance (Belleville 1956), with cross-tolerance to psilocybin (Isbell 1961); spacing doses at least several days apart preserves effect.
- Microdosing breaks: Twice-weekly dosing for 8 weeks showed no tolerance in a MindBio-sponsored trial (Daldegan-Bueno 2026); common practice adds several weeks off after 1–2 months to reassess benefit.
Sourcing and Quality
- Pharmaceutical-grade forms: Trials use LSD base in solution (Basel) or lysergide D-Tartrate tablets (Definium); bioequivalence (equal absorption) of base and tartrate was tested in Basel (NCT04865653).
- Reputable sources: No commercial brand or compounding-pharmacy product is identified; quality-controlled pharmaceutical-grade preparations are available only through registered trials (NCT04865653) or exceptional licences from Switzerland’s Federal Office of Public Health (FOPH), which names LSD among eligible banned narcotics (FOPH banned-narcotics licences; FOPH exceptional licences).
- Illicit blotter risk: In Brazilian police seizures, the share of blotters containing LSD fell from 100% in 2011 to 0.1% in 2014 as NBOMes and other drugs replaced it (de Souza Boff 2020).
- NBOMe toxicity: A review reports that NBOMes sold as LSD cause seizures, hyperthermia (dangerous overheating) and deaths (Zawilska 2020).
- What to look for: Laboratory analysis by chromatography with mass spectrometry (separating and identifying molecules) is the reliable test; reagent kits are only presumptive, a drug-checking review notes (Hirschfeld 2026).
- Stability: LSD degrades with light, heat and moisture, so stored material is kept cold and dark; dose content of illicit units is unknown.
Practical Considerations
- Time to effect: After a single dose, anxiety scores fell from day 2 (Definium Voyage press release) and depression scores by week 1, both staying lower through week 12 (Definium Emerge press release).
- Common pitfalls: Taking unverified blotters, combining with lithium, dosing without a sober monitor, and expecting microdoses to deliver the effects of full-dose sessions, which a meta-analysis of controlled trials has not shown (Meshkat 2026).
- Regulatory status: Schedule I under United States federal law (21 CFR 1308.11). The sponsor plans an FDA new drug application in the first half of 2027 (Definium Panorama press release).
- Access and cost: Legal access is limited to clinical trials and Swiss case-by-case exceptional licences for medical use of banned narcotics (FOPH exceptional licences), a category that names LSD (FOPH banned-narcotics licences); sessions require 8 or more hours of clinical monitoring, which drives cost.
- Payer incentives: A single monitored dose competes with years of daily generic antidepressants; insurers may favor whichever is cheaper over their coverage horizon, which can bias coverage and research priorities either way.
- Sponsor incentives: LSD was first synthesized in 1938, so investment centers on proprietary formulations; the company funding the largest trials benefits from positive results, and the Basel group has run a trial it sponsored (NCT05200936).
Interaction with Foundational Habits
- Sleep: Potentiating at microdoses: 10 µg every third day lengthened sleep by 24.3 minutes the following night versus placebo in a MindBio-sponsored trial (Allen 2024). Full doses taken late can delay sleep onset, so morning dosing protects the night.
- Nutrition: Indirect: no food–drug interaction studies exist. Nausea affects 34–40% at 100 µg (Robison 2025; Holze 2022), so a light, low-fat meal before dosing and lack of appetite during sessions are expected.
- Exercise: Blunting during sessions: impaired balance occurred in 36% at 100 µg (Holze 2022), so training is deferred until the next day. No studies link LSD to training adaptations; microdoses did not impair balance in older adults (Family 2020).
- Stress management: Direct: LSD acutely raises plasma cortisol (a stress hormone) (Schmid 2015) yet lowers anxiety over following weeks (Holze 2023). Breathing and meditation skills practiced beforehand are commonly used to navigate difficult moments.
Monitoring Protocol & Defining Success
Before a first session, a baseline assessment establishes eligibility and reference values: psychiatric history including family history of psychosis, a medication review for lithium and serotonergic drugs, resting blood pressure and heart rate, an electrocardiogram if cardiac risk factors exist, a pregnancy test where relevant, validated anxiety and depression questionnaires, and optionally CYP2D6 genotyping. People planning repeated microdosing add a baseline echocardiogram.
Ongoing monitoring follows this cadence: blood pressure and heart rate before dosing and hourly during full-dose sessions until effects resolve (about 6–12 hours); questionnaires at 1 week, 4 weeks and 12 weeks after a session, then every 3 months if further sessions are considered; for microdosing, questionnaires every 4 weeks and an echocardiogram every 6–12 months while dosing continues.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Blood pressure | Below 120/80 mmHg (2017 ACC/AHA guideline) | Safety check: high values defer or stop dosing | ACC/AHA: American College of Cardiology/American Heart Association (Whelton 2018), societies whose members treat hypertension; conventional reference range 90–120/60–80 mmHg; LSD adds about 12 mmHg systolic (Holze 2022); measure seated after 5 minutes’ rest |
| Resting heart rate | 60–100 beats/min (standard reference range) | Safety check: tachycardia defers dosing | Tachycardia means a fast heart rate above 100 beats/min; LSD raised peak heart rate above 100 in 20% at 100 µg (Holze 2022); pair with blood pressure |
| CYP2D6 genotype | No established target; record metabolizer status as a personal baseline | Safety check: poor metabolizers warrant a lower dose | One-time genetic test; poor metabolizers have about 75% higher exposure (Vizeli 2021); paroxetine and other CYP2D6 inhibitors mimic poor-metabolizer status |
| Echocardiogram (heart valve structure) | No established target; track change from the individual’s own baseline | Safety check: new valve thickening stops repeated dosing | Relevant to regular microdosing; no changes over 8 weeks in one study (Daldegan-Bueno 2026); a systematic review rates the risk theoretical (Xu 2026) |
| GAD-7 anxiety score | 0–4, minimal anxiety (Spitzer 2006 severity bands) | Expected to change: tracks anxiety response | GAD-7: Generalized Anxiety Disorder 7-item questionnaire (Spitzer 2006); no conventional laboratory reference range exists for questionnaire scores; same time of day each assessment |
| PHQ-9 depression score | 0–4, minimal depression (Kroenke 2001 severity bands) | Expected to change: tracks depression response | PHQ-9: Patient Health Questionnaire 9-item (Kroenke 2001); scores of 5, 10, 15 and 20 mark mild to severe depression; no conventional laboratory reference range exists; also screens suicidality |
| Pregnancy test (urine hCG) | Negative (standard reference range) | Safety check: positive result excludes dosing | hCG: human chorionic gonadotropin, the pregnancy hormone; test within 48 hours before each full-dose session |
Qualitative markers of success:
- Anxiety, worry and rumination in daily life
- Mood stability and interest in usual activities
- Sleep quality on nights after sessions or microdoses
- Sense of meaning and connectedness reported after sessions
- Absence of persisting visual disturbances, paranoia or suicidal thoughts
- Alcohol intake, where reduced drinking is a goal
Emerging Research
- Voyage, Phase 3, generalized anxiety (214 participants): NCT06741228 reported a positive 12-week primary result; a 40-week open-label extension (everyone knows the treatment) continues to April 2027. Durable extension benefit would strengthen the anxiety case; fading benefit would favor repeated dosing.
- Panorama, Phase 3, generalized anxiety (245 participants): NCT06809595 reported a positive 12-week result; its extension runs to May 2027. Peer-reviewed positive data would confirm the replicated anxiety benefit; null extension data would limit conclusions to short-term relief.
- Emerge, Phase 3, major depression (149 participants): NCT06941844 reported positive preliminary results; completion is February 2027. Peer review confirming them would resolve the depression conflict toward benefit; weaker full results would keep it conflicted.
- Ascend, Phase 3, major depression (165 participants): NCT07592689 is recruiting. A positive result would replicate the depression benefit; a null result would leave depression graded on conflicted evidence.
- Alcohol use disorder, Phase 2 (128 participants, Basel): NCT05474989 is recruiting. A positive result would give the historical alcohol benefit modern confirmation; a null result would weaken it substantially.
- Cluster headache, Phase 2 (65 participants, Radboud): NCT05477459 is recruiting. A positive result would lift cluster headache above survey-level evidence; a null result would leave only uncontrolled reports.
- Cluster headache, Phase 2 (30 participants, Basel): NCT03781128 passed its registered December 2025 completion date; the record still lists recruiting and no results are posted.
- Antipsychotic and sedative rescue study (20 participants, Basel): NCT05964647 completed in June 2025; no results are posted or published, so the effects of olanzapine and lorazepam rescue after LSD remain unreported.
- Palliative care, Phase 2 (60 participants, Basel): NCT05883540 is recruiting. A positive result would extend illness-related anxiety benefit to palliative patients; a null result would narrow it.
- Microdosing for premenstrual disorders (150 participants): NCT07189299 is not yet recruiting. A positive result would give microdosing its first controlled clinical benefit; a null result would reinforce the negative microdosing evidence.
- Microdosing for depression (LSDDEP2, 89 participants; no NCT ID): Against an active placebo (a comparator with noticeable effects) (Daldegan-Bueno 2024), this trial completed in 2025 (ACTRN12624000128594) with no MADRS difference at 8 weeks (29.9% versus 36.4% reduction; MindBio LSDDEP2 press release), contradicting an open-label 59.5% reduction (Daldegan-Bueno 2026); peer review is pending.
- Valve safety with repeated dosing: A 2026 systematic review found no human cases of LSD-linked valve disease but called for cardiac monitoring (Xu 2026); long-term echocardiographic data could confirm or remove this concern.
- Aging biology: LSD extended worm lifespan through serotonin receptors (Carrilho 2026); vertebrate lifespan studies would show whether this translates beyond invertebrates.
- Blinding and expectancy: A review finds expectancy effects may inflate psychedelic trial results (Szigeti 2024); trials using active placebos could weaken or confirm current effect sizes.
Conclusion
LSD is a long-acting psychedelic that changes perception and mood by acting on a brain chemical receptor. For health-focused adults, the evidence divides by how it is used.
Full-dose sessions under supervision have the strongest support. Replicated controlled trials show lasting relief of persistent anxiety after one or two sessions, and older trials point the same way for problem drinking, though with uncertain staying power. Relief of depression looks similar in direction, but part of that evidence is mixed and the largest study has not yet been through independent review. Much of the newest evidence comes from the company developing an LSD tablet, which also holds rights to the main academic group’s data, and older studies were often funded by groups that promote psychedelic therapy.
Repeated very small doses, the form most common among people seeking better mood, focus or brain health, have not shown lasting benefits over placebo in healthy adults, despite brief mood lifts on dosing days. Ideas about slower brain aging or longer life rest on cell, worm and mouse studies.
The main risks are temporary: intense or frightening experiences, nausea, headache, and rises in blood pressure and heart rate during the session. Serious mental health reactions are rare and cluster in people with existing psychiatric illness or a family history of psychosis. A heart valve concern with frequent long-term dosing remains theoretical. Lithium, unverified illicit products and unsupervised settings account for much of the avoidable harm, and the legal status limits access to research settings.